No Government Money, No Problem for Moderna and Pfizer

A Food and Drug Administration committee will meet Tuesday to discuss how to move forward with the next generation of vaccines ahead of a booster campaign this fall. Paying for them is another matter.

Congress has so far failed to approve additional funding for the shots — bad news for the U.S. population at large, but not bad at all for vaccine makers. They will just charge higher prices in the private market. The White House is already preparing to ration its vaccine supply to the most vulnerable Americans, according to White House coronavirus coordinator Dr. Ashish Jha. For Modern the first manufacturer to release data for an updated vaccine based on the Omicron variant of Covid-19, this could herald a new phase of the pandemic.

Leave a Comment